| Project/Area Number |
20590536
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Hamamatsu University School of Medicine |
|---|
Principal Investigator |
INUI Naoki Hamamatsu University School of Medicine, 医学部・臨床薬理学, 助教 (80402254)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
WATANABE Hiroshi 浜松医科大学, 医学部, 教授 (50262803)
CHIDA Kingo 浜松医科大学, 医学部, 准教授 (40197611)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2010: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2009: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 薬物治療学 / 薬物代謝酵素 / 個別化治療 / 抗癌剤S-1 / 肺癌 / CYP2A6 / 抗癌剤S1 |
|---|
| Research Abstract |
The frequencies of the CYP2A6^*4C was 17.4%. In the S-1 pharmacokinetic analysis, the area under the concentration-time curve from 0 to 10 hours (AUC) ratios of 5-FU/tegafur showed large interindividual variabilities, ranging from 5.14 to 112.6. The AUC for tegafur was 1.5-fold higher in patients with the CYP2A6^*4C allele than in patients without the CYP2A6^*4C allele. Patients with the CYP2A6^*4C allele had a significantly lower maximum plasma concentration for 5-FU than patients without the CYP2A6^*4C allele.
|
